Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: Nuplazid
Published 2026-02-15 · Last reviewed 2026-02-22 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Pimavanserin (brand Nuplazid) is approved for hallucinations and delusions associated with Parkinson’s disease psychosis (PDP) (label).
Unlike most antipsychotics, pimavanserin does not meaningfully block dopamine receptors. This matters in Parkinson’s disease because D2 blockade can worsen motor symptoms; pivotal trials found improvement in psychosis without worsening motor ratings compared with placebo (label/trial).
Pimavanserin carries the antipsychotic boxed warning about increased mortality in elderly patients with dementia-related psychosis and is not approved for dementia-related psychosis unless symptoms are related to Parkinson’s disease (label).
QT prolongation is a key safety consideration; baseline risk review and interaction checks are typically part of prescribing (label/clinical).
In clinical practice, management of PDP often includes addressing reversible contributors (infection, medication changes, sleep disruption) and considering off-label antipsychotics; pimavanserin is often selected when avoiding dopamine blockade is a priority (review/clinical).
Response is typically assessed over several weeks, with reassessment of diagnosis, triggers, and safety (falls/confusion) if symptoms do not improve (clinical).
The compare view, pimavanserin evidence feed, and pimavanserin print page support documentation and counseling when treatment choices overlap with sedation, falls, and QT concerns.
Often used when PDP symptoms are distressing and when avoiding dopamine blockade is a priority. Safety planning frequently focuses on QT risk, confusion/delirium risk, and drug interactions via CYP3A4.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Selective serotonin 5-HT2A inverse agonist/antagonist with minimal dopamine receptor activity, targeting psychosis symptoms without the typical motor side effects of D2 blockade (label/mechanism).
5-HT2A modulation is relevant to psychosis in Parkinson’s disease and related neurodegenerative disorders (mechanism).